Cutler Group’s Verona Pharma VRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$3K Sell
200
-210
-51% -$3.63K ﹤0.01% 1775
2023
Q4
$8K Sell
410
-800
-66% -$11.8K ﹤0.01% 2543
2023
Q3
$19K Buy
1,210
+200
+20% +$3.85K ﹤0.01% 2086
2023
Q2
$21K Buy
1,010
+730
+261% +$15.6K ﹤0.01% 1832
2023
Q1
$5K Sell
280
-1,804
-87% -$39K ﹤0.01% 2767
2022
Q4
$54K Buy
2,084
+1,692
+432% +$22.5K ﹤0.01% 1526
2022
Q3
$4K Buy
+392
New +$3.3K ﹤0.01% 3870
2021
Q1
Sell
-200
Closed -$1K 6368
2020
Q4
$1K Hold
200
﹤0.01% 4600
2020
Q3
$1K Buy
+200
New +$1.38K ﹤0.01% 4485

Other funds holding VRNA

Cutler Group's VRNA Position: Q1 2024 in Review

Cutler Group reduced its Verona Pharma (VRNA) stake by 51% in Q1 2024, selling an estimated $3.63K and leaving 200 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1775.

Cutler Group first reported a position in VRNA in Q3 2020 and has held it in 9 quarters since. The position peaked at $54K in Q4 2022. 113 funds tracked by Wall St. Rank hold VRNA as of Q1 2024.

  • Cutler Group held 200 shares of Verona Pharma worth $3K as of Q1 2024.
  • Cutler Group sold 210 Verona Pharma shares in Q1 2024, an estimated $3.63K.
  • Verona Pharma made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1775 holding.
  • Cutler Group first reported a position in Verona Pharma in Q3 2020 and has held it in 9 quarters since.
  • Cutler Group's Verona Pharma position peaked at $54K in Q4 2022.
  • 113 funds tracked by Wall St. Rank held Verona Pharma as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.